Understanding bleeding risks from blood thinners in cancer patients
Official title: Prediction of Anticoagulant-Related Bleeding Risk in Patients with Cancer
Funded at Washington University · NIH-10983348 · Data updated 2026-11-12
This study is looking to create a helpful tool that can predict which cancer patients on blood thinners might be at risk for serious bleeding, so doctors can make safer choices about their treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | January 5, 2023 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $389,391 |
| NIH project number | 5R01HL166386-03 |
| Project ID | NIH-10983348 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients who are currently receiving anticoagulant therapy for conditions such as venous thromboembolism.
✕Less likely to help
Patients who are not on anticoagulant therapy or those without a cancer diagnosis may not benefit from this research.
What this research studies
This research aims to develop a predictive model to assess the risk of major bleeding in cancer patients who are receiving anticoagulant therapy. Given that patients with cancer face a significantly higher risk of bleeding compared to those without cancer, the study will analyze various factors to create an evidence-based approach for managing anticoagulant use. By identifying patients at high risk for bleeding, healthcare providers can make more informed decisions about anticoagulant therapy, potentially reducing unnecessary risks while still preventing blood clots. The research will involve collecting data from cancer patients on anticoagulants and calibrating the predictive model based on their unique health profiles.
Why it matters
Potential benefit: If successful, this research could lead to safer anticoagulant management for cancer patients, reducing the incidence of life-threatening bleeding events.
How similar studies have gone: While there are existing models for predicting bleeding risk in non-cancer populations, this research is novel as it focuses specifically on cancer patients, addressing a significant gap in current medical knowledge.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Sanfilippo, Kristen Marie — Washington University
- Study coordinator: Sanfilippo, Kristen Marie
Related research
Other NIH-funded projects on the same topics.
-
Direct measurement of RhD sensitization after early-pregnancy bleeding
This study tests how often Rh immunoglobulin given after bleeding in early pregnancy prevents RhD sensitization in pregnant people.
-
EpiMAX: a new injectable gel that stops GI bleeding quickly and for days
A new injectable hydrogel with epinephrine-loaded microparticles is designed to plug GI bleeds and provide immediate and lasting hemostasis for about 72 hours.
-
Dynamic risk tools to prevent blood clots and bleeding in cancer patients
A new AI-based approach will predict who among people with cancer starting treatment is at higher risk for blood clots or dangerous bleeding, helping doctors tailor preventive care.
-
Bleeding and Platelet Problems in Ehlers-Danlos Syndrome
This NIH grant looks at why people with Ehlers-Danlos syndrome bleed more and how platelet function is involved, with goals that could lead to better care during surgery or emergencies.
-
Long-acting RNA therapy to control fibrinolysis and reduce bleeding
A new RNA treatment delivered in lipids aims to slow down fibrinolysis and lessen bleeding for people with bleeding disorders or severe hemorrhage.
-
Thrombosis and Bleeding Risk in Medical Inpatients
A patient-facing program to better predict who is at risk for blood clots or bleeding during and after hospital stays, and to tailor prevention accordingly.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.